Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Profit After Tax (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Profit After Tax data on record, last reported at -$64.7 million in Q4 2025.

  • For Q4 2025, Profit After Tax fell 33.62% year-over-year to -$64.7 million; the TTM value through Dec 2025 reached -$265.9 million, down 37.43%, while the annual FY2025 figure was -$265.9 million, 37.43% down from the prior year.
  • Profit After Tax reached -$64.7 million in Q4 2025 per OCUL's latest filing, up from -$69.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $3.1 million in Q1 2021 and bottomed at -$69.4 million in Q3 2025.
  • Average Profit After Tax over 5 years is -$30.9 million, with a median of -$26.7 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: surged 122.25% in 2021, then tumbled 6972.29% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$3.8 million in 2021, then tumbled by 303.69% to -$15.5 million in 2022, then tumbled by 88.01% to -$29.2 million in 2023, then tumbled by 65.6% to -$48.4 million in 2024, then tumbled by 33.62% to -$64.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$64.7 million in Q4 2025, -$69.4 million in Q3 2025, and -$67.8 million in Q2 2025.